This review discusses how metformin may reduce breast cancer risk in patients with type 2 diabetes, suggesting potential mechanisms.
A BSTRACT The incidence of diabetes is markedly increasing worldwide. In addition to cardiovascular complications, many epidemiological studies have demonstrated that diabetic patients have a markedly increased risk of developing many types of cancer and several meta-analyses have found that metformin, the most commonly prescribed medication for type 2 diabetes, is associated with a lower risk of developing several cancers. Therefore, the suggested mechanism of metformin in the reduction of breast cancer will be discussed in this review.
No takes yet. Share an insight, caveat, or question.
Sahil Kongala (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: